Versant Capital Management Inc Boosts Holdings in Insulet Co. (NASDAQ:PODD)

Versant Capital Management Inc raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 106.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 305 shares of the medical instruments supplier’s stock after buying an additional 157 shares during the period. Versant Capital Management Inc’s holdings in Insulet were worth $80,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new stake in shares of Insulet in the 2nd quarter worth $32,000. Commonwealth Equity Services LLC increased its position in Insulet by 24.7% in the second quarter. Commonwealth Equity Services LLC now owns 16,531 shares of the medical instruments supplier’s stock worth $3,336,000 after buying an additional 3,272 shares in the last quarter. Natixis Advisors LLC raised its stake in shares of Insulet by 13.6% in the second quarter. Natixis Advisors LLC now owns 24,607 shares of the medical instruments supplier’s stock worth $4,966,000 after buying an additional 2,955 shares during the period. Rhumbline Advisers lifted its position in shares of Insulet by 0.5% during the 2nd quarter. Rhumbline Advisers now owns 146,561 shares of the medical instruments supplier’s stock valued at $29,576,000 after buying an additional 757 shares in the last quarter. Finally, Private Advisor Group LLC increased its holdings in Insulet by 92.6% in the 2nd quarter. Private Advisor Group LLC now owns 3,187 shares of the medical instruments supplier’s stock worth $643,000 after acquiring an additional 1,532 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PODD shares. Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Canaccord Genuity Group increased their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Raymond James boosted their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Trading Up 3.7 %

Shares of NASDAQ PODD opened at $266.30 on Friday. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business’s 50 day moving average is $260.30 and its two-hundred day moving average is $227.97. The stock has a market capitalization of $18.68 billion, a P/E ratio of 45.60, a PEG ratio of 4.12 and a beta of 1.21.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.